Amplification of ARID4B was detected in up to 20% of human prostate cancer cases (Supplementary Fig. 1a, left), while deletion and loss-of-function mutation of PTEN are frequent (Supplementary Fig. 1a, right). Here, ARID4B is linked to prostate carcinoma.